We're at this year’s #EHA2024 Hybrid Congress in Madrid, Spain to present our latest research on difficult-to-treat blood cancers and disorders. Every year, the European Hematology Association (EHA) unites healthcare professionals from around the world to exchange insights and work together to address some of the greatest unmet needs in #hematology. If you are a healthcare professional attending the congress, please visit us at Booth number C04 – we look forward to connecting with you!
Jazz Pharmaceuticals’ Post
More Relevant Posts
-
MedicReS AI General Director | Data Science | Machine Learning | Artificial Intelligence | Mentor | Investor | Conversational and Generative Artificial Intelligence
AI in Hematology: AI transforming blood disease analysis. #AIHematology #MedicresAI2024 #cancer #hematology www.medicres.ai
-
-
This week, Michael and Josh take on G3 advanced neuroendocrine tumours, a complex and challenging obstacle in the field of Oncology. The higher the grade, the more aggressive the disease. Michael's insightful overview highlights the lack of efficacy of platinum chemotherapies in this well-differentiated cohort, while Josh's systematic review focuses on the promising potential of CAPTEM (temozolamide and capecitabine). Stay up-to-date with the things medical oncology as we tackle this constantly changing specialty #NeuroendocrineTumours #CancerResearch #CAPTEM #Chemotherapy #MedicalResearch Michael Fernando https://lnkd.in/gdrECQNt
-
A groundbreaking study has been published in the Journal of Hematology and Oncology, shedding light on an intriguing medical phenomenon. Titled "Acute Onset Symptomatic Polycythemia Vera," this research delves into the complexities of myeloproliferative neoplasms (MPNs), particularly focusing on a case where polycythemia vera (PV) manifested dramatically post-splenectomy. Key Takeaways: PV, a chronic myeloproliferative neoplasm, often evolves slowly and insidiously. This study presents a unique case where PV was masked by a low-grade lymphoma until it presented acutely after a splenectomy. Despite not meeting the diagnostic criteria initially, molecular confirmation of PV was made a year later due to persistent clinical features. The findings underscore the importance of considering "acute onset" MPNs post-splenectomy, urging for a more molecular investigative approach to avert serious complications. 🔬 For a detailed exploration of this intriguing case and its implications, dive into the full article here: https://lnkd.in/gwuznmwU Stay informed, stay curious! 💡 #Research #MedicalScience #MPN #PV #AcademicDiscovery
-
-
SAVE THE DATE: May 31st & June 1st in Padua! "XXX Giuseppe Basso Summer Interlab Meeting in Pediatric Hematology Oncology" The meeting aims to discuss and compare laboratory and research activities as well as the different collaborations and growth of #AIEOP. Topics will include acute lymphoblastic #leukemia; acute myeloid leukemias, #lymphomas, solid tumors and other pediatric hematologic diseases. We look forward to receiving your abstracts by Friday, May 10th! 🗓 Università degli Studi di Padova Azienda Ospedale Università Padova #oncologia #ematologia #ricerca #childhoodcancer
-
The future of personalized medicine and therapeutic optimization: Notable's Predictive Precision Medicine Platform (PPMP). What is it? How does it work? and Why you'll want to know about it...all at the American Society of Hematology (#ash2023), BOOTH #2454. biomedwoRx: Life Sciences Consulting #aml #mds #hematology
MEET US AT ASH! Mark your calendar to visit Notable at Booth #2454 at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition December 9-12, 2023, in San Diego, CA. Schedule a meeting to learn about our Predictive Precision Medicine Platform (PPMP) and our lead therapeutic, volasertib, a highly potent PLK1 inhibitor proven to induce cell cycle arrest and apoptosis in various cancer cells. Contact us through LinkedIn message or https://lnkd.in/eAgN3cFt before Monday, Dec 11th for an exclusive event invitation! #ASH23 #hematology #hematologists #bloodcancer #precisionmedicine #AML #MDS
-
-
Gastrointestinal (GI) cancers are at the forefront of personalized medicine. Coming off of American Society of Clinical Oncology (ASCO) GI 2024, our team is sharing some insightful takeaways around the theme of “taking personalized care to the next level.” What were the key highlights? Read more to find out: https://lnkd.in/eK9dvZV3 #GI24 #ASCO #oncology #medicine #lifesciences
“Personalized” battle against GI cancers: Highlights from ASCO GI 2024 - Putnam
-
📚 Just published in the Journal of Hematology and Oncology: "Extraosseous Plasmacytoma of Thyroid Arising in Hashimoto’s Thyroiditis." ℹ️ This study delves into the rare occurrence of plasma cell neoplasms in the thyroid gland, either as primary extraosseous plasmacytoma or as secondary involvement by multiple myeloma. 👩🔬 In a fascinating case study, a 62-year-old female presented with goiter and Hashimoto’s thyroiditis, but the histologic diagnosis revealed an unexpected extraosseous plasmacytoma. 🔍 Through detailed analysis including immunohistochemistry and PCR, researchers ruled out multiple myeloma, highlighting the importance of considering plasmacytoma in patients with thyroid enlargement and autoimmune thyroiditis. 📖 For more insights into this intriguing study, read the full article here: https://lnkd.in/gc_mE_48 #Research #ThyroidHealth #Plasmacytoma #HashimotosThyroiditis #MedicalScience
-
Chief Executive Officer at USA and International Research Inc.
1moExcited to learn about your latest research in difficult-to-treat blood cancers and disorders at #EHA2024!